What Is AOD-9604?

AOD-9604 represents amino acids 176–191 from the C-terminal end of human growth hormone, with an added tyrosine residue at the N-terminus for stabilization. This 16-amino acid peptide fragment retains the lipolytic activity of GH while lacking the receptor binding domains responsible for growth, IGF-1 stimulation, and glucose metabolism disruption.

The compound advanced through Phase II clinical trials conducted by Metabolic Pharmaceuticals (now Calzada Limited) in Australia, demonstrating statistically significant weight loss in obese subjects. While it did not progress to Phase III, AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA in 2014 for use as a food supplement ingredient — a notable distinction that underscores its favorable safety profile. It continues to be actively researched for fat loss and cartilage repair applications.

AOD-9604 promotes fat reduction through mechanisms distinct from full-length growth hormone:

• Beta-3 adrenergic receptor activation — AOD-9604 stimulates lipolysis (fat breakdown) through beta-3 adrenergic receptor pathways in adipose tissue, mimicking the fat-burning effect of GH.
• Lipogenesis inhibition — The peptide suppresses the formation of new fat cells and reduces fatty acid synthase activity, preventing new fat storage.
• No IGF-1 stimulation — Unlike full GH or GHRH analogues, AOD-9604 does not increase IGF-1 levels, eliminating growth-related side effects and proliferative concerns.
• No glucose metabolism disruption — AOD-9604 does not affect insulin sensitivity or blood glucose levels, a significant advantage over exogenous GH.
• Cartilage regeneration — Emerging research shows AOD-9604 stimulates proteoglycan and collagen production in chondrocytes, suggesting applications in osteoarthritis and joint repair.

Research spanning preclinical and clinical studies has identified several potential benefits:

• Fat loss — Phase II clinical trials showed statistically significant reductions in body weight compared to placebo in obese subjects over 12 weeks.
• Targeted adipose reduction — AOD-9604 appears to preferentially mobilize abdominal and visceral fat stores.
• No muscle wasting — Fat loss occurs without the catabolic effects on lean tissue sometimes seen with caloric restriction.
• Cartilage repair — Studies in osteoarthritis models demonstrate increased proteoglycan synthesis and cartilage matrix production.
• Favorable safety profile — GRAS status and clinical trial data support a high margin of safety at effective doses.
• No GH side effects — Absence of IGF-1 elevation means no concerns about joint pain, insulin resistance, or cellular proliferation associated with GH therapy.

AOD-9604 is typically administered via subcutaneous injection:

• Standard dose — 300 mcg per day, injected subcutaneously into abdominal fat.
• Timing — Best administered in the morning on an empty stomach, at least 30 minutes before eating. Some protocols split into two 150 mcg doses (morning and pre-bed).
• Cycle duration — Research protocols typically run 8–12 weeks. Some studies have used 12–24 week protocols with consistent results and no significant adverse events.
• Oral formulations — The original Phase II trials used oral AOD-9604 at doses of 1 mg per day, though subcutaneous injection provides more reliable bioavailability.

Reconstituted AOD-9604 should be stored refrigerated at 2–8°C and used within 30 days. Avoid shaking the vial — gently swirl bacteriostatic water against the lyophilized powder.

AOD-9604 has one of the most favorable safety profiles among peptides studied for body composition:

• Well-tolerated in clinical trials — Phase II studies reported adverse event rates comparable to placebo.
• No hormonal disruption — AOD-9604 does not affect GH, IGF-1, insulin, cortisol, or thyroid hormone levels.
• Injection site reactions — Mild, transient redness or discomfort at the injection site has been reported.
• Headache — Occasional mild headaches noted in clinical trials.
• GRAS designation — FDA GRAS status (2014) supports the compound's safety when used appropriately.

AOD-9604 is sold for research purposes only and is not FDA-approved as a drug for any indication. The GRAS status applies only to its use as a food supplement ingredient. This article is for informational purposes only and does not constitute medical advice.

AOD-9604 is widely available from research peptide vendors. When selecting a source, prioritize:

• Independent COAs — Third-party HPLC and mass spectrometry verification confirming ≥98% purity.
• Proper lyophilization — The product should arrive as a fine white powder without clumping or discoloration.
• Vendor reputation — Check community reviews and forums for consistent quality feedback.

Ascension Peptides offers AOD-9604 at 99%+ purity with independent third-party testing and batch-specific COAs. Their US-based fulfillment center ships within 24 hours, delivering in 2–3 business days with proper cold chain handling. Competitive pricing and responsive customer support make them our top recommendation for AOD-9604 sourcing in 2026.